Preclinical and Phase 1 data support the evaluation of SRK-015 in ongoing Phase 2 trial for the treatment of patients with Type 2 and Type 3 spinal muscular trophy CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) — Scholar Rock (SRRK), a clinical-stage...
“If you have a patient who complains that their sleep has taken a turn for the worse then there is reason to open the door to a question about suicide,” says Vaughn McCall, MD, chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia...
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). “In a Phase 2 clinical trial, zilucoplan...
MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum BURLINGTON, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC...
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for an oral presentation at the Society for Immunotherapy of Cancer...
Mark Terry for Biospace writes: It was a moderately busy week for clinical trial news. Here’s a look. Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a...
Email
Text